Craft

Caribou Biosciences

Stock Price

$1.6

2024-07-05

Market Capitalization

$144.5 M

2024-07-05

Revenue

$34.5 M

FY, 2023

Caribou Biosciences Summary

Company Summary

Overview
Caribou Biosciences is a leading biotechnology company in genome engineering. We develop technology-based solutions for cellular engineering and analysis based on the CRISPR-Cas9 technology platform. Cas9, when paired with a guide RNA, cuts double-stranded DNA allowing for specific changes to DNA. These site-specific DNA modifications can be utilized to carry out sophisticated gene knock-outs or knock-ins. Caribou's technologies mark a revolutionary development that allows scientists to engineer nearly any part of any genome with extreme flexibility. Forbes Magazine has called Cas9 the protein that "could change biotech forever" and the New York Times has noted that "the pace of new discoveries and applications is dizzying." Caribou's tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology.
Type
Public
Status
Active
Founded
2011
HQ
Berkeley, CA, US | view all locations
Website
http://cariboubio.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Rachel Haurwitz

    Rachel Haurwitz, President and Chief Executive Officer

    • Barbara McClung

      Barbara McClung, Chief Legal Officer and Corporate Secretary

      • Jason O'Byrne

        Jason O'Byrne, Chief Financial Officer

        LocationsView all

        1 location detected

        • Berkeley, CA HQ

          United States

          2929 Seventh Street

        Caribou Biosciences Financials

        Summary Financials

        Revenue (Q1, 2024)
        $2.4M
        Net income (Q1, 2024)
        ($41.2M)
        Cash (Q1, 2024)
        $49.4M
        EBIT (Q1, 2024)
        ($46.0M)
        Enterprise value
        $160.2M

        Footer menu